Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on 2018 and his first full year as Contagion®'s editor-in-chief.
December 2018
This orphan drug is for patients with limited antiretroviral treatment options.
Expanding the differential for diarrhea beyond Clostridium difficile.
Providers in other states can learn from this multiorganization collaborative that aims to improve antimicrobial utilization and prevent the emergence of antimicrobial resistance across South Carolina.
Nicola Petrosillo, MD, discusses current controversies in C difficile prevention and treatment.
Dr. Goff and Mr. Nosta discuss how to use Twitter to communicate about infectious diseases and antimicrobial stewardship.
A collaborative, international effort aims to answer tough antimicrobial resistance questions.
Despite increased research and investigations, the cause of the spike in cases of AFM in the United States remains unknown.
Invasive aspergillosis affects up to 13% of immunocompromised patients who are in the hospital.
The synthetic novel tetracycline offers a new option for complicated intra-abdominal infections.
Advertisement
Advertisement
Trending on Contagion Live
1
Rapid HCV Test Provides Opportunity for Single Visit Diagnosis and Treatment Encounters
2
No Negative Impact for Individuals Taking Lenacapavir and Gender-Affirming Hormone Therapy
3
Phage and Antibiotic Combination Therapy for Biofilm-Associated Bacterial Infections
4
A Versatile Option for Complex Infections
5
